Key highlights

  • All eight resolutions at the 13 October 2026 AGM were decided on a poll.
  • The remuneration report received 98.77% of votes cast in favour, and the three director re-elections each received at least 99.14%.
  • Additional Placement capacity under Listing Rule 7.1A was approved with 96.62% in favour.

Control Bionics Limited (ASX:CBL) is a neurotechnology medical device company whose products include the NeuroNode wearable sensor and related assistive technology. The company held its Annual General Meeting on Tuesday, 13 October 2026 and released the results of the meeting the same day, in accordance with section 251AA of the Corporations Act 2001.

Latest development

Each of the eight resolutions was decided on a poll. On the poll, the remuneration report received 102,064,937 votes for (98.77%) and 1,272,108 against (1.23%). The re-elections of Damian Lismore, Stephen Rix and Professor Nicholas Opie were carried with 99.14%, 99.65% and 99.14% in favour respectively.

The meeting also approved the issue of 1,044,087 shares to Stephen Rix (98.19% for), the issue of Options to the Executive Director (98.18%), the Control Bionics Employee Share Option Plan (98.63%) and additional share issue capacity under Listing Rule 7.1A (96.62%). Proxy discretion votes of 2,170,000 were recorded on each item.

Company operating model and operations

Control Bionics develops and commercialises electromyography-based technology for people with limited ability to communicate or control devices. Its announcements describe a range that includes the NeuroNode, the NeuroStrip and the DROVE wheelchair controller, and operations across North America, Australia, Europe and Japan. The company has been pursuing a strategy of wholesale distribution of the NeuroNode through partners.

Why the development matters

The results confirm the board composition and the equity-related approvals available to the company. Approval of the Employee Share Option Plan and the Listing Rule 7.1A capacity gives the company additional flexibility to issue securities within the limits set by the resolutions. Resolution 1, the remuneration report, is advisory and the results table records no outcome for it.

Risks and uncertainties

Resolution 8 had the highest level of abstentions, at 96,727,151 votes, and a lower proxy approval rate of 88.40% before the poll, although it was carried. Issuing shares or options under the approvals may dilute existing holders. The meeting results do not address the company's trading performance, funding position or commercial progress.

Operational risks for a medical device company include regulatory approvals, reimbursement coverage, distribution partner performance and the pace of sales growth.

What to watch next

Shareholders may watch for how the company uses the new Employee Share Option Plan and the Listing Rule 7.1A capacity, any share or option issues to directors under the approved resolutions, and the company's next quarterly activities report for operating and Cash Flow updates.